This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

IDEV's Pivotal SUPERB Trial Demonstrates SUPERA® Stent Significantly Exceeds VIVA Criteria For One-Year Patency In Femoropopliteal Artery Disease

LAS VEGAS and WEBSTER, Texas, Oct. 10, 2012 /PRNewswire/ -- IDEV Technologies, Inc. (IDEV) today announced positive clinical outcomes for its SUPERB pivotal clinical trial of its SUPERA® Peripheral Stent System. This Food and Drug Administration (FDA) Investigational Device Exemption (IDE) trial demonstrated the highest patency rates in peripheral stent trials for superficial femoral or proximal popliteal artery disease that has been publically reported. In addition, this is the first and only femoral-popliteal artery IDE trial to record zero stent fractures for nitinol-based technologies. The SUPERA stent is a highly differentiated, disruptive and proprietary interwoven nitinol wire technology platform that offers significantly improved radial strength, flexibility and kink resistance, which is designed to adapt to the anatomy. Kenneth Rosenfield, M.D., Section Head for Vascular Medicine and Intervention at Massachusetts General Hospital and study co-principal investigator, presented the 12-month outcomes from SUPERB in the Late Breaking Trials session of the 10 th VIVA Conference held in Las Vegas, Nevada.  

The SUPERB study enrolled 264 patients at 34 centers across the country, treating 266 lesions with a mean length of 8 cm. De novo or restenotic lesions in the superficial femoral and proximal popliteal arteries of 40-140 mm in length were enrolled. Key results included:
  • The primary safety endpoint of freedom from death, target lesion revascularization (TLR) or any amputation of the index limb to 30 days post-procedure, was met by 99.6 percent of the patients.
  • The study also exceeded the primary efficacy endpoint with a statistically significant improvement over the objective performance goal established by the FDA and VIVA Physicians, Inc. for vessel patency at one year. 
  • Based on survival analysis, the SUPERA stent achieved freedom from loss of primary patency at one year of 86 percent.
  • Freedom from TLR of 90 percent
  • Zero reported stent fractures at one year.

"In the SUPERB trial, the SUPERA stent achieved one-year patency rates not previously achieved in a pivotal trial for any stent placed in the SFA and proximal popliteal artery," said Dr. Rosenfield. "The unique design of the SUPERA stent and its combination of flexibility and radial strength may account for this stent's ability to restore durable patency."

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.66 -0.09%
FB $118.58 0.85%
GOOG $698.30 0.76%
TSLA $241.82 0.44%
YHOO $36.53 -0.19%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.10 +15.80 0.77%
NASDAQ 4,818.3090 +42.9510 0.90%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs